Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this currently Zacks Rank #3 (Hold) company have risen 15.3% in the past six months compared with the industry’s 13.6% growth. The S&P 500 Index has also increased 12.7% in the same time frame.Glaukos, with a market capitalization of $4.3 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects ...